4242 Campus Point Court
Tocagen is developing first-in-class, broadly applicable product candidates for the treatment of cancer using our cancer-selective gene therapy platform built on retroviral replicating vectors, or RRVs, initially for patients with recurrent high grade glioma, or HGG.
Our broadly applicable product candidates are designed to activate a patient’s immune system against their own cancer from within.
At the core of our approach is a gene therapy platform that utilizes RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our proprietary platform is designed to fight cancer through a combination of mechanisms without the autoimmune toxicities that patients commonly experience with other treatments. In other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ healthy tissue intact while the tumor is destroyed.
Stock Symbol: TOCA
Stock Exchange: NASDAQ
This animation demonstrates the proposed mechanism of action for Tocagen’s lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC, and is based primarily on preclinical data.
Toca 511 & Toca FC is an investigational therapy, which has not been proven to be safe or effective for any use and is not approved by the U.S. Food and Drug Administration or any other government agency.
Tocagen is developing broadly applicable, cancer-selective immunotherapy treatments for cancer, including high grade glioma, a type of brain cancer. The company’s lead product combines Toca 511 with Toca FC. The therapeutic regimen involves two discrete steps with Toca 511 given first followed by treatment with Toca FC.
95 articles with Tocagen
Study Published In Science Translational Medicine Reports Favorable Safety And Extended Survival For Brain Cancer Patients Treated With Tocagen Inc.'s Cancer-Selective Viral Gene Therapy
Tocagen Inc. Announces Presentations At The 2016 BIO International Convention And Boston CEO Conference
Tocagen Inc. To Present Data From Clinical Trials And Preclinical Programs At Four Scientific Conferences
First Patient Enrolled In Toca 5, Tocagen Inc.'s Phase II/III Clinical Trial In Patients With Recurrent Glioblastoma Or Anaplastic Astrocytoma
Tocagen Inc. Presents Interim Data From Studies Evaluating Toca 511 & Toca FC At The Annual Meeting Of The Society For Neuro-Oncology (SNO)
Tocagen Inc. To Present Interim Results From Studies Evaluating Toca 511 & Toca FC At The Annual Meeting Of The Society For Neuro-Oncology (SNO)
FDA Grants Orphan Drug Designation For Tocagen Inc.'s Toca 511 & Toca FC, An Investigational Immuno-Oncology Treatment For Glioblastoma
FDA Grants Fast Track Designation To Tocagen Inc.'s Toca 511 & Toca FC For Treatment Of Recurrent High Grade Glioma
Tocagen Inc. Presents Updated Interim Survival Data From Ongoing Clinical Studies At American Association Of Neurological Surgeons (AANS)/Congress Of Neurological Surgeons (CNS) Section On Tumors
Tocagen Inc. To Present Updated Interim Results From Studies Evaluating Toca 511 & Toca FC At The American Association Of Neurological Surgeons (AANS)/Congress Of Neurological Surgeons (CNS) Section On Tumors